AR076973A1 - Composicion tensioactiva reconstituida mejorada que contiene analogos de la proteina tensioactiva b (sp-b) y de la proteina tensioactiva c (sp-c) - Google Patents
Composicion tensioactiva reconstituida mejorada que contiene analogos de la proteina tensioactiva b (sp-b) y de la proteina tensioactiva c (sp-c)Info
- Publication number
- AR076973A1 AR076973A1 ARP100101970A ARP100101970A AR076973A1 AR 076973 A1 AR076973 A1 AR 076973A1 AR P100101970 A ARP100101970 A AR P100101970A AR P100101970 A ARP100101970 A AR P100101970A AR 076973 A1 AR076973 A1 AR 076973A1
- Authority
- AR
- Argentina
- Prior art keywords
- surfactant
- protein
- tensioactive
- native
- weight
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/395—Alveolar surfactant peptides; Pulmonary surfactant peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0082—Lung surfactant, artificial mucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- General Preparation And Processing Of Foods (AREA)
- Cosmetics (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
Abstract
Un agente tensioactivo pulmonar reconstituido que comprende un vehículo lipídico y una combinacion de un polipéptido análogo a la proteína tensioactiva SP-C nativa con un polipéptido particular análogo a la proteína tensioactiva SP-B nativa. Formulaciones farmacéuticas que contienen dicho agente tensioactivo, y su uso para el tratamiento o la profilaxis del RDS y de otros trastornos respiratorios. Reivindicacion 1: Una composicion tensioactiva reconstituida caracterizada porque comprende a) entre 1,2 y 1,8% en peso de un polipéptido análogo a la proteína tensioactiva SP-C nativa, que consiste en la secuencia representada por la formula IPSSPVHLKRLKLLLLLLLLILLLILGALLLGL (SEQ ID N°:1); b) entre 0,1 y 0,5% en peso de un polipéptido análogo a la proteína tensioactiva SP-B nativa, que consiste en la secuencia representada por la formula CWLCRALIKRIQALIPKGGRLLPQLVCRLVLRCS (SEQ ID N°:2); un fosfolípido monoinsaturado y un fosfolípido saturado en una proporcion en peso que varía entre 45:55 y 55:45; donde todas las cantidades están calculadas sobre la base del peso total del agente tensioactivo reconstituido. Reivindicacion 2: El agente tensioactivo reconstituido de acuerdo con la reivindicacion 1, caracterizado porque comprende a) aproximadamente 1,5% en peso de un polipéptido análogo a la proteína tensioactiva SP-C nativa, que consiste en la secuencia representada por la formula IPSSPVHLKRLKLLLLLLLLILLLILGALLLGL (SEQ ID N°:1); b) aproximadamente 0,2% en peso de un polipéptido análogo a la proteína tensioactiva SP-B nativa, que consiste en la secuencia representada por la formula CWLCRALIKRIQALIPKGGRLLPQLVCRLVLRCS (SEQ ID N°:2); c) 1,2-dipalmitoil-sn-glicero-3-fosfocolina (DPPC) y 1-palmitoil-2-oleil-sn-glicero-3-fosfoglicerol (POPG), en una proporcion en peso de aproximadamente 50:50; donde todas las cantidades están calculadas sobre la base del peso total del agente tensioactivo reconstituido.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09162052 | 2009-06-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR076973A1 true AR076973A1 (es) | 2011-07-20 |
Family
ID=41055357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101970A AR076973A1 (es) | 2009-06-05 | 2010-06-03 | Composicion tensioactiva reconstituida mejorada que contiene analogos de la proteina tensioactiva b (sp-b) y de la proteina tensioactiva c (sp-c) |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US8399406B2 (es) |
| EP (1) | EP2438086B1 (es) |
| JP (1) | JP5666569B2 (es) |
| KR (1) | KR101668137B1 (es) |
| CN (1) | CN102459327B (es) |
| AR (1) | AR076973A1 (es) |
| AU (1) | AU2010256066B2 (es) |
| BR (1) | BRPI1010120B1 (es) |
| CA (1) | CA2764454C (es) |
| CL (1) | CL2011003003A1 (es) |
| CO (1) | CO6470858A2 (es) |
| CY (1) | CY1118676T1 (es) |
| DK (1) | DK2438086T3 (es) |
| EA (1) | EA021163B1 (es) |
| ES (1) | ES2621974T3 (es) |
| GE (1) | GEP20135967B (es) |
| HK (1) | HK1166332A1 (es) |
| HR (1) | HRP20170445T1 (es) |
| HU (1) | HUE034053T2 (es) |
| IL (1) | IL216718A (es) |
| JO (1) | JO3226B1 (es) |
| LT (1) | LT2438086T (es) |
| MA (1) | MA33374B1 (es) |
| ME (1) | ME01279B (es) |
| MX (1) | MX2011012951A (es) |
| MY (1) | MY159464A (es) |
| NZ (1) | NZ596848A (es) |
| PE (1) | PE20120541A1 (es) |
| PL (1) | PL2438086T3 (es) |
| PT (1) | PT2438086T (es) |
| SG (1) | SG176305A1 (es) |
| SI (1) | SI2438086T1 (es) |
| TN (1) | TN2011000558A1 (es) |
| TW (1) | TWI457132B (es) |
| UA (1) | UA103526C2 (es) |
| WO (1) | WO2010139442A1 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8968786B2 (en) | 2007-06-22 | 2015-03-03 | Board Of Regents, The University Of Texas System | Formation of stable submicron peptide or protein particles by thin film freezing |
| CA2829629A1 (en) * | 2011-03-10 | 2012-09-13 | Board Of Regents, The University Of Texas System | Protein nanoparticle dispersions |
| EP2812018B1 (en) * | 2012-02-09 | 2018-12-05 | University Of Rochester | Novel sp-b&sp-c peptides, synthetic lung surfactants, and use thereof |
| ES2644317T3 (es) | 2012-11-21 | 2017-11-28 | Chiesi Farmaceutici S.P.A. | Tensioactivos pulmonares reconstituidos |
| CN104382942A (zh) * | 2014-11-05 | 2015-03-04 | 烟台东诚药业集团股份有限公司 | 一种猪肺表面活性物质混悬液制备新工艺 |
| EP3106090A1 (en) | 2015-06-15 | 2016-12-21 | CHIESI FARMACEUTICI S.p.A. | System for effective breath-synchronized delivery of medicament to the lungs |
| CN107666933A (zh) | 2015-04-22 | 2018-02-06 | 奇斯药制品公司 | 用于药物有效地呼吸同步递送到肺部的方法和系统 |
| US11311691B2 (en) | 2015-04-28 | 2022-04-26 | Chiesi Farmaceutici S.P.A | Device for facilitating the administration of a medicament to the lung by a catheter |
| EP3452041A4 (en) * | 2016-03-07 | 2020-11-11 | Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center | COMPOSITIONS AND METHOD OF ADMINISTRATION OF PPAR AGONISTS, SURFACTANT PEPTIDES AND PHOSPHOLIPIDS |
| CA3028551A1 (en) | 2016-07-28 | 2018-02-01 | Chiesi Farmaceutici S.P.A. | Method and system for delivery of an aerosolized medicament |
| KR102395835B1 (ko) | 2016-08-24 | 2022-05-10 | 키에시 파르마슈티시 엣스. 피. 에이. | 재구성된 폐 계면활성제 조성물을 포함하는 안정한 약제학적 제제 |
| BR112019008169A2 (pt) | 2016-10-26 | 2019-07-09 | Chiesi Farm Spa | dispositivo para facilitar o posicionamento de um cateter, sistema para entrega de um medicamento em aerossol por meio de um cateter, método para utilização de um dispositivo e kit |
| EP3558376B1 (en) | 2016-12-22 | 2021-10-20 | Chiesi Farmaceutici S.p.A. | A therapeutic combination comprising a pulmonary surfactant and a steroid for the treatment of evolving bpd |
| TW201927286A (zh) | 2017-12-15 | 2019-07-16 | 義大利商凱西製藥公司 | 用於噴霧投藥之包含肺表面張力素的藥學調配物 |
| WO2019115771A1 (en) | 2017-12-15 | 2019-06-20 | Pari Pharma Gmbh | Nebuliser system, holding system, combination comprising nebuliser system and holding system, and aerosol administration method |
| AU2019260526A1 (en) | 2018-04-23 | 2020-11-19 | Chiesi Farmaceutici S.P.A. | A therapeutic combination comprising a pulmonary surfactant and a steroid for the prophylaxis of BPD |
| EP3666316A1 (en) | 2018-12-14 | 2020-06-17 | PARI Pharma GmbH | Aerosol delivery device and method of operating the aerosol delivery device |
| EP3666315A1 (en) | 2018-12-14 | 2020-06-17 | PARI Pharma GmbH | Aerosol delivery device and method of operating the aerosol delivery device |
| EP3843105A1 (en) | 2019-12-23 | 2021-06-30 | PARI Pharma GmbH | Control device for aerosol nebulizer system |
| US20230257446A1 (en) | 2020-01-28 | 2023-08-17 | Chiesi Farmaceutici S.P.A. | Polypeptides having improved properties |
| EP4366691A1 (en) | 2021-07-05 | 2024-05-15 | Chiesi Farmaceutici S.p.A. | Process for the preparation of a pulmonary surfactant |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2372558A1 (en) | 1999-06-11 | 2000-12-21 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Pharmaceutical preparation containing modifications of surfactant protein b (sp-b) and surfactant protein c (sp-c) |
| ITMI20021058A1 (it) * | 2002-05-17 | 2003-11-17 | Chiesi Farma Spa | Miscele di lipidi sintetici ottimizzate per la preparazione di un surfattante ricostituito |
| EP1481665A1 (en) * | 2003-05-30 | 2004-12-01 | CHIESI FARMACEUTICI S.p.A. | Novel lipid mixtures for synthetic surfactants |
| KR101243867B1 (ko) * | 2005-05-11 | 2013-03-20 | 야마사 쇼유 가부시키가이샤 | 폐서팩턴트 단백질의 안정화법 |
| WO2008011559A2 (en) | 2006-07-20 | 2008-01-24 | University Of Rochester | Synthetic lung surfactant and use thereof |
| DK2078038T3 (da) * | 2006-10-13 | 2013-12-02 | Chiesi Farma Spa | Rekonstituerede surfaktanter med forbedrede egenskaber |
| EP1997502A1 (en) * | 2007-06-01 | 2008-12-03 | CHIESI FARMACEUTICI S.p.A. | Reconstituted surfactants having improved properties |
-
2010
- 2010-05-27 US US12/788,480 patent/US8399406B2/en active Active
- 2010-05-31 KR KR1020117028394A patent/KR101668137B1/ko active IP Right Grant
- 2010-05-31 CA CA2764454A patent/CA2764454C/en active Active
- 2010-05-31 CN CN201080024545.6A patent/CN102459327B/zh active Active
- 2010-05-31 DK DK10724708.2T patent/DK2438086T3/en active
- 2010-05-31 BR BRPI1010120-9A patent/BRPI1010120B1/pt active IP Right Grant
- 2010-05-31 LT LTEP10724708.2T patent/LT2438086T/lt unknown
- 2010-05-31 PT PT107247082T patent/PT2438086T/pt unknown
- 2010-05-31 MA MA34471A patent/MA33374B1/fr unknown
- 2010-05-31 GE GEAP201012486A patent/GEP20135967B/en unknown
- 2010-05-31 PL PL10724708T patent/PL2438086T3/pl unknown
- 2010-05-31 ME MEP-2011-197A patent/ME01279B/me unknown
- 2010-05-31 EA EA201190292A patent/EA021163B1/ru unknown
- 2010-05-31 SI SI201031433A patent/SI2438086T1/sl unknown
- 2010-05-31 UA UAA201114285A patent/UA103526C2/ru unknown
- 2010-05-31 AU AU2010256066A patent/AU2010256066B2/en active Active
- 2010-05-31 HU HUE10724708A patent/HUE034053T2/en unknown
- 2010-05-31 JP JP2012513503A patent/JP5666569B2/ja active Active
- 2010-05-31 EP EP10724708.2A patent/EP2438086B1/en active Active
- 2010-05-31 MX MX2011012951A patent/MX2011012951A/es active IP Right Grant
- 2010-05-31 SG SG2011089299A patent/SG176305A1/en unknown
- 2010-05-31 MY MYPI2011005866A patent/MY159464A/en unknown
- 2010-05-31 WO PCT/EP2010/003293 patent/WO2010139442A1/en active Application Filing
- 2010-05-31 NZ NZ596848A patent/NZ596848A/xx unknown
- 2010-05-31 PE PE2011002046A patent/PE20120541A1/es active IP Right Grant
- 2010-05-31 ES ES10724708.2T patent/ES2621974T3/es active Active
- 2010-06-03 TW TW099117884A patent/TWI457132B/zh active
- 2010-06-03 JO JOP/2010/0185A patent/JO3226B1/ar active
- 2010-06-03 AR ARP100101970A patent/AR076973A1/es not_active Application Discontinuation
-
2011
- 2011-11-04 TN TNP2011000558A patent/TN2011000558A1/en unknown
- 2011-11-25 CL CL2011003003A patent/CL2011003003A1/es unknown
- 2011-12-01 IL IL216718A patent/IL216718A/en active IP Right Grant
- 2011-12-02 CO CO11166483A patent/CO6470858A2/es active IP Right Grant
-
2012
- 2012-07-18 HK HK12107033.0A patent/HK1166332A1/xx unknown
-
2017
- 2017-02-24 CY CY20171100262T patent/CY1118676T1/el unknown
- 2017-03-21 HR HRP20170445TT patent/HRP20170445T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR076973A1 (es) | Composicion tensioactiva reconstituida mejorada que contiene analogos de la proteina tensioactiva b (sp-b) y de la proteina tensioactiva c (sp-c) | |
| AR113422A2 (es) | Agentes tensioactivos reconstituidos que tienen propiedades mejoradas | |
| BRPI0811320A2 (pt) | Surfactantes reconstituídos com propriedades melhoradas | |
| CU20130033A7 (es) | Imidazopiridazinas sustituidas | |
| BR112014009087A2 (pt) | formulações de etanercept estabilizadas com xilitol | |
| AR068302A1 (es) | Peptidos para vacunas para canceres que expresan antigenos asociados con tumores | |
| AR093569A1 (es) | Tensioactivos pulmonares reconstituidos | |
| CL2018003178A1 (es) | Composición farmacéutica | |
| AR079639A1 (es) | Composicion de pasta de dientes anti-erosiva | |
| AR102779A1 (es) | Composición farmacéutica, su preparación y sus usos | |
| BRPI0813619A2 (pt) | peptídeos surfactantes pulmonares sintéticos | |
| PE20030837A1 (es) | Tensioactivos pulmonares que contienen una polimixina para mejorar las propiedades superficiales | |
| RS20170169A1 (sr) | Poboljšana rekonstituisana kompozicija sufraktanta koja sadrži analoge sufraktanta proteina b (sp-b) i surfaktanta proteina c (sp-c) | |
| Jeong et al. | Different strategies for producing naturally soluble form of common cytokine receptor γ chain | |
| TH135738A (th) | องค์ประกอบสารลดแรงตึงผิวที่ถูกสร้างใหม่ (reconstituted surfactant composition) ซึ่งถูกปรับปรุง ที่ประกอบด้วยแอนะล็อกส์ของโปรตีนของสารลดแรงตึงผิว b(sp-b) และโปรตีนของสารลดแรงตึงผิว c (sp-c) | |
| CL2022001035A1 (es) | Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas | |
| AR104372A1 (es) | Lípido glucopiranosil a y formulaciones de alergénos para administración sublingual |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |